3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
18
Prostatic Neoplasms
6
Carcinoma, Renal Cell
5
Uveal Melanoma
4
Sarcoma
4
Histiocytoma, Malignant Fibrous
4
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Vulvar Neoplasms
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Urethral Neoplasms
2
Thyroid Neoplasms
2
Ovarian Neoplasms
2
Nasopharyngeal Carcinoma
2
Myelodysplastic Syndromes
2
Liposarcoma
2
Leukemia
2
Gastrointestinal Stromal Tumors
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Transitional Cell
2
Carcinoma, Hepatocellular
2
Carcinoma, Endometrioid
2
Bone Neoplasms
2
Vaginal Neoplasms
1
Urogenital Neoplasms
1
Ureteral Neoplasms
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Interventions
Abiraterone Acetate
5
enzalutamide
4
abiraterone
3
Prednisone
3
apalutamide
2
Nivolumab
2
Docetaxel
2
pembrolizumab
1
niraparib
1
darolutamide
1
cabazitaxel
1
Pluvicto
1
Omeprazole
1
Ipilimumab
1
Drug Therapy
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prostatic Neoplasms, Castration-Resistant
×
CTLA-4 Antigen
×
Clear all
NCT04717154
2026-01-06
INSPIRE
Radboud University Medical Center
Phase 2
Completed
69 enrolled